All News
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
Halberd announced that preliminary testing of its extracorporeal laser irradiation methodologies completely eradicated Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF).
The collaboration covers the co-development and co-commercialization of products created from Foghorn’s BRM oncology program and another oncology target.
A study out of the University of Oxford found that two shots of the Pfizer-BioNTech vaccine or the AstraZeneca-Oxford vaccine were not as effective at against Omicron as they were against previous variants.
Arena Pharmaceuticals’ share price nearly doubled in premarket trading after Pfizer announced it was acquiring the company and its diverse portfolio of developmental and clinical assets.
Novartis is going full steam ahead with its cancer development efforts, recently posting positive results from two ongoing trials for lymphoma and leukemia.
Orca-T demonstrated significantly higher graft-versus-host disease-free, relapse-free survival (GRFS) rates compared to patients who received standard of care.
The following features are highlights from the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in-person in Atlanta, GA, and virtually from December 11 to 14.
Now, researchers are on the threshold of great changes that have the potential to transform non-curable diseases into those that can be cured.
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
Shares of Moderna are down nearly 10% this morning despite the company posting positive interim results from an experimental seasonal flu vaccine.
Innocoll Biotherapeutics, Genapsys, and Adicet Bio announced today their relocation and expansion plans.
Roche announced promising results from the Phase II CITYSCAPE study of tiragolumab plus Tecentriq compared to Tecentriq alone as a treatment for PD-L1-positive metastatic NSCLC.
A new study conducted on a 35-year-old blood and stool sample provides new insights into HIV research and the role the gut microbiome may have played in infection among infected individuals.
A team of Yale researchers has found a key to unlocking the deadly mystery of brain aneurysms in adults.
The 2021 San Antonio Breast Cancer Symposium is meeting December 7–10 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, and virtually.
Eli Lilly forged a multi-year collaborative partnership with China-based Regor Therapeutics Group to discover and develop new therapies that will be aimed at metabolic disorders.
The best way to battle the dominant Delta strain is booster vaccines. So far, initial data suggests boosters are likely to help battle Omicron as well. For that and more COVID-19 news, read on.
A U.S. Congress subcommittee unanimously approved the ACT for ALS bill in a decision that could soon pour massive funding into the search for treatment for this debilitating and deadly disease.
CSL Behring and uniQure announced that their etranacogene dezaparvovec hit the pre-specified primary endpoint in their Phase III clinical trial in severe to moderately severe hemophilia B.